Immunomic Therapeutics, Inc.
Berat, Southern Albania, Albania · Biotechnology · 50 employees
The privately-held biotechnology company is pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors. It has established proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tumors, including colorectal, pancreatic, mesothelioma, ovarian and breast cancer.
Funding history
- Funding Round — $6.5M — Jun 2025
- Funding Round — $3.0M — Apr 2024
- Funding Round — $77.7M — Jan 2021
- Funding Round — $10.0M — Feb 2020
- Funding Round — $315K — Aug 2018
Recent signals
- Jun 02, 2025: Raised $6.5M
- Nov 06, 2024: Launched Immunomic Therapeutics, Inc. presents its UNITE® platform for RNA vaccines at SITC 39th Annual Meeting 2024.
- Apr 10, 2024: Raised $3.0M
- Jan 14, 2021: Raised $77.7M
- Feb 26, 2020: Raised $10.0M
- Aug 03, 2018: Raised $315K
- Mar 15, 2017: Raised $77.7M
See plans & pricing → Track Immunomic Therapeutics, Inc.’s funding, hiring, and signals — with verified contacts — on Fundz.